



Tetratherix Limited
ACN 607 771 077

SUPPLEMENTARY PROSPECTUS

Important Information

This is a supplementary prospectus (**Supplementary Prospectus**) which supplements and is intended to be read with the prospectus dated 4 June 2025 (**Prospectus**) issued by Tetratherix Limited (ACN 607 771 077) (**Company**).

This Supplementary Prospectus is dated 12 June 2025 and was lodged with ASIC on that date.

ASIC, the ASX and their respective officers take no responsibility for the contents of this Supplementary Prospectus.

This Supplementary Prospectus should be read together with the Prospectus. Other than as set out below, all details in relation to the Prospectus remain unchanged. Terms and abbreviations defined in the Prospectus have the same meaning in this Supplementary Prospectus. If there is a conflict between the Prospectus and this Supplementary Prospectus, this Supplementary Prospectus will prevail.

This Supplementary Prospectus will be issued with the Prospectus as an electronic prospectus, copies of which can be downloaded from the website of the Company at <https://tetratherix.com/prospectus/>.

This is an important document and should be read in its entirety. If you do not understand it, you should consult your professional advisers without delay.

This Supplementary Prospectus is intended to be read with the original Prospectus dated 4 June 2025 issued by Tetratherix Limited (ACN 607 771 077).

1. Purpose of this Supplementary Prospectus

The purpose of this Supplementary Prospectus is to provide additional information to investors (as set out in Sections 3 below) following feedback from ASIC.

2. No investor action required

The Directors believe that the changes in this Supplementary Prospectus are not materially adverse from the point of view of an investor. Further, no Application Forms have been available prior to release of this Supplementary Prospectus and no applications have been received or processed by the Company. Accordingly, no additional investor action is required. An investor may lodge an Application Form in the manner set out in Section 6.8 of the Prospectus.

3. Updates to the Prospectus

3.1 Letter from the Founder

The Letter from the Founder on pages vii and viii of the Prospectus is deleted in its entirety.

3.2 Letter from the Chair

Paragraph 3 of the Letter from the Chair on page (ix) of the Prospectus is deleted and replaced with the following, which inserts the words underlined below:

"The opportunity ahead of Tetratherix is rare and meaningful. We have a target of three initial clinical applications: bone regeneration, tissue spacing, and tissue healing. With these three applications alone, our current total addressable market opportunity exceeds US\$6.8 billion. Please note this is an estimate only and may not eventuate, see Section 3.2(c) for further details. However, the broader implication of Tetramatrix is its capacity to augment and enhance existing treatments across a wide spectrum of medical applications. More importantly, we are pioneering new ways to access these markets—ways that place clinicians and patients at the centre of everything we do."

Paragraph 9 of the Letter from the Chair on page (ix) of the Prospectus is also deleted and replaced with the following, which deletes the words "We are clear about the challenges ahead", and inserts the words "The Company has not yet generated revenue and the Company's Auditor issued an unqualified opinion that contained a material uncertainty related to going concern":

"As with all companies, there are risks, including the time and complexity required to commercialise new medical technologies. The Company has not yet generated revenue and the Company's Auditor issued an unqualified opinion that contained a material uncertainty related to going concern. These risks are detailed in Section 3 of the Prospectus and should be considered carefully, specifically the risk that Tetratherix may not successfully commercialise its platform technology, achieve regulatory clearances in some markets or may not be profitable for a period of time - all or some resulting in the need for further capital requirements."

This Supplementary Prospectus is intended to be read with the original Prospectus dated 4 June 2025 issued by Tetratherix Limited (ACN 607 771 077).

3.3 Section 1.6

The second bullet point in clause 1.6 of the Prospectus is deleted and replaced with the following, which replaces the word "enable" with the words "will enable":

"Clinically modular and protected: the Tetramatrix™ platform technology has potential clinical utility across different fields of medicine from bone regeneration to oncology spacing and tissue healing. The Tetramatrix™ platform technology will enable the development of innovative solutions allowing physicians to treat patients outside the typical hospital settings, providing cheaper and faster access to healthcare with improved outcomes for patients. The main composition of the Tetramatrix™ platform technology is a proprietary polymer that is protected by 36 granted patents in major markets. For information on the jurisdictional coverage please refer to the Intellectual Property Report at Annexure B."

The fourth bullet point of clause 1.6 of the Prospectus is also deleted and replaced with the following, which replaces the words "are then licensed" with "will then be licensed" and the word "supplying" with "will supply":

"Low risk commercialisation model: leveraging the Company's intellectual property strategy and patent portfolio, the Tetramatrix™ platform technology is used to develop multiple products in parallel which will then be licensed to market leaders in their specific fields. The Company manufactures the Tetramatrix™ platform polymers, will supply them as finished goods to the licensing partners. The Company plans to enter into further agreements with multiple market leaders in different market segments for sales and distribution of different products through their established infrastructure, reducing the need for expensive in-market sales and distribution infrastructure and related expenses for the Company."

3.4 Clause 1.7

The first paragraph of clause 1.7 of the Prospectus is deleted and replaced with the following, which deletes the word "manufacture" and replaces it with the word "develop":

"The Company has used its Tetramatrix™ platform technology to develop and provide tailored products in three markets: bone regeneration, tissue spacing and tissue healing. The total addressable market (TAM) for all biomaterials as a whole in these three markets is collectively expected to be US\$6.8 billion in CY2025 and is anticipated to grow to US\$9.5 billion by CY2030. The long-term market opportunity for the Company extends beyond just these three markets with the development of further derivative products from the Tetramatrix™ platform technology."

3.5 Clause 2.1

The second paragraph on page 44 of the Prospectus of the Prospectus under the subheading "Introduction" is deleted and replaced with the following, which deletes the word "developed" and replaces it with the words "that are under development":

"All products that are under development by using the Tetramatrix™ platform technology come in ready-to-use syringes, filled with the water-based solutions (Figure 2 below). The physical presentation of all product configurations is the same and their chemistry is >95% identical allowing interchangeable use of the underlying intellectual property, manufacturing

This Supplementary Prospectus is intended to be read with the original Prospectus dated 4 June 2025 issued by Tetratherix Limited (ACN 607 771 077).

and safety and efficacy data sets. The syringes and their contents are sterilised for easy handling by clinical staff and thus fitting seamlessly into existing workflows."

The third paragraph on page 44 of the Prospectus is also deleted and replaced with the following, which adds that all products under development are not yet commercialised; refers to the expected market entry timeline disclosed in the Prospectus; and clarifies the applications of the platform for certain uses that are under development:

"The Company currently has a portfolio of well-progressed products that leverage the core Tetramatrix™ platform technology. It is important to note that all products under development are not yet commercialised and their expected market entry timeline is presented in Section 2.10. These will include the applications of the platform for bone regeneration, tissue spacing in oncological and ophthalmic settings and tissue healing to reduce scarring."

The fourth paragraph on page 44 of the Prospectus is also deleted and replaced with the following, to specify the unique commercial strategy, denoted as a flywheel that involves the interchangeable use of underlying safety and performance dataset and licensing different products, developed with the Tetramatrix™ platform technology to leading medical companies for co-development:

"The Company uses a unique commercial strategy, denoted as a flywheel that involves interchangeable use of underlying safety and performance dataset and licensing different products, developed with the Tetramatrix™ platform technology to leading medical companies for co-development. The Company manufactures these products and will supply them to partners under upcoming sale and distribution agreements. These arrangements are structured as long-term partnerships or joint ventures, enabling the Company to quickly launch multiple products while focusing on ongoing development of new products, utilising the Tetramatrix™ platform technology. The Company and Henry Schein have provisionally agreed to enter into a partnership agreement to commercialise and expand the clinical application of a derived product from the Tetramatrix platform technology for dental and oral applications. The Company is also in commercial negotiations with leading global companies for another product derived from Tetramatrix™ platform technology for orthopaedic applications. The Company has an established joint venture with Tutelix which includes industry-leading clinicians to commercialise a derivative product from Tetramatrix platform technology for interventional urology. The Company has also executed a memorandum of understanding to establish a similar joint venture with BioOptix to commercialise its ophthalmic-tissue spacing products based on the Tetramatrix™ platform technology."

3.6 **Clause 2.5**

The following additional words are included immediately underneath the third dot point in clause 2.5 of the Prospectus:

"Important to note that all products under development are not yet commercialised and their time to market is outlined in Section 2.10."

4. **Consents**

The Company confirms that as at the date of this Supplementary Prospectus, each of the parties that have been named as having consented to being named in the Prospectus have not withdrawn that consent.

5. **Authorisation**

This Supplementary Prospectus is issued by the Company and its issue has been authorised by a resolution of the Directors.

In accordance with section 720 of the Corporations Act, each Director has consented to the lodgement of this Supplementary Prospectus with ASIC and has not withdrawn that consent.

This Supplementary Prospectus is signed for and on behalf of the Company by:



Emma Cleary
Non-Executive Chair

Dated: 12 June 2025

This Supplementary Prospectus is intended to be read with the original Prospectus dated 4 June 2025 issued by Tetratherix Limited (ACN 607 771 077).